Xspray Pharma (BATS-CHIXE:XSPRAS) - Stock Price, News & Analysis

XSPRAS Stock Overview

A pharmaceutical company, engages in the development of protein kinase inhibitors for targeted cancer treatments in Sweden. More details

XSPRAS fundamental analysis
Snowflake Score
Valuation	1/6
Future Growth	5/6
Past Performance	0/6
Financial Health	4/6
Dividends	0/6

Rewards

Earnings are forecast to grow 122.45% per year

Risk Analysis

Has less than 1 year of cash runway

Makes less than USD$1m in revenue (SEK0)

Shares are highly illiquid

Shareholders have been diluted in the past year

Xspray Pharma AB (publ) Competitors

Faron Pharmaceuticals Oy

AIM:FARN

UK£175.2m

Avacta Group

AIM:AVCT

UK£173.8m

Bioventix

AIM:BVXP

UK£197.0m

e-therapeutics

AIM:ETX

UK£52.6m

Price History & Performance

Summary of all time highs, changes and price drops for Xspray Pharma
Historical stock prices
Current Share Price	SEK 71.20
52 Week High	SEK 0
52 Week Low	SEK 0
Beta	0.92
11 Month Change	0%
3 Month Change	n/a
1 Year Change	n/a
33 Year Change	n/a
5 Year Change	n/a
Change since IPO	44.28%

Recent updates

Shareholder Returns

	XSPRAS	GB Biotechs	GB Market
7D	0%	4.1%	1.7%
1Y	n/a	-14.2%	9.0%

Return vs Industry: Insufficient data to determine how XSPRAS performed against the UK Biotechs industry.

Return vs Market: Insufficient data to determine how XSPRAS performed against the UK Market.

Price Volatility

Is XSPRAS's price volatile compared to industry and market?
XSPRAS volatility
XSPRAS Average Weekly Movement	n/a
Biotechs Industry Average Movement	7.6%
Market Average Movement	4.8%
10% most volatile stocks in GB Market	10.4%
10% least volatile stocks in GB Market	2.6%

Stable Share Price: XSPRAS has not had significant price volatility in the past 3 months.

Volatility Over Time: Insufficient data to determine XSPRAS's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
2003	26	Per Andersson	www.xspraypharma.com

Xspray Pharma AB (publ), a pharmaceutical company, engages in the development of protein kinase inhibitors for targeted cancer treatments in Sweden. The company’s product candidates include Dasynoc, a trailblazer, under approval phase for the treatment of chronic myeloid leukemia and acute lymphoblastic leukemia; XS003, an amorphous non-crystalline nilotinib, under pivotal studies for the treatment of chronic myeloid leukemia; XS008, based on axitinib, under development for treatment of kidney cancer; and XS00Y under development phase. It has partnership agreements with EVERSANA for the commercialization of Dasynoc, as well as with NerPharMa for commercial production of Dasynoc.

Xspray Pharma AB (publ) Fundamentals Summary

How do Xspray Pharma's earnings and revenue compare to its market cap?
XSPRAS fundamental statistics
Market cap	SEK 1.75b
Earnings (TTM)	-SEK 214.76m
Revenue (TTM)	n/a

0.0x

P/S Ratio

-8.1x

P/E Ratio

Is XSPRAS overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
XSPRAS income statement (TTM)
Revenue	SEK 0
Cost of Revenue	SEK 0
Gross Profit	SEK 0
Other Expenses	SEK 214.76m
Earnings	-SEK 214.76m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

Nov 06, 2024

Earnings per share (EPS)	-6.36
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	0%

How did XSPRAS perform over the long term?

See historical performance and comparison

Xspray Pharma BATS-CHIXE:XSPRAS Stock Report